Industry News
Industry News
15.47 billion IPO Xinguangwei Business Analysis
2022-03-14 Views: 782


Introduction of Xinguangwei Company

We are a medical device company in China, focusing on the research and development and commercialization of medical endoscopes and related products. Our core product uses electronic endoscopic product series at one time, which has been approved by four disposable use of electronic endoscopy products (including one product that is commercialized in Europe) and ten disposable use of electronic endoscopes. Research product composition. Our product portfolios also include ten reusable medical endoscopes suitable for multiple clinical departments and ten endoscope equipment compatible with endoscopy products. As of the last actual possible date, nine of these products have been approved for commercialization (including four commercial endoscopy equipment), and the remaining eleven research products are in different development stages. During the trading record, we mainly reached income from reusable internal spare complication equipment (especially 4K medical endoscopy camera system and 3D image imaging device), and we have not yet carried out large -scale sales of core products. According to the data of Fhstana, China ’s use of medical endoscopes is highly concentrated, and several international medical device giants dominate the market. The penetration rate of domestic brands in 2020 is only 5.6%. Our goal is to continuously improve market penetration to break the long -term monopoly situation of international brands in the Chinese medical endoscopy market, and may generate large costs in the future. In addition, our core products can only be used for endoscopic image processing devices (for one -time use products). Therefore, we may need to generate additional costs to penetrate our core products in the Chinese market.

 

learn more

Copyright © Shanghai Keensea Medical Technology Co., Ltd. . All Rights Reserved Case number:Shanghai ICP No. 2022020046 -1 Technical Support:Web design